KBI Biopharma, Inc. and Selexis SA Expand Executive Leadership Team with the Appointment of Abdelaziz Toumi, Ph.D. as Chief Business Officer
Read More
Selexis offers comprehensive and rapid solutions for the development of stable, high-yield, and clonal mammalian cell lines that are used in recombinant protein drug manufacturing.
By combining SUREtechnology Platform™ and world-class expertise, Selexis SURE Cell Line Development™ Services significantly reduce the time, effort, and costs that are associated with the development of high-performance mammalian cell lines for therapeutic protein production (e.g., development of monoclonal antibodies, bi-specific monoclonal antibodies, growth factors, Fc Fusions and enzymes).
The development of high-yield production cell lines starts with the cloning of the gene of interest into SUREtech Vectors™ that bear Selexis SGE® (Selexis Genetic Elements). These optimally designed DNA expression vectors are then transfected into the fully documented Selexis SURE CHO-M Cell Line™ using the SUREfection™ procedure.
By applying single cell cloning from the selected stable pools, Selexis identifies high-expressing clonal cell lines that are then evaluated for their growth characteristics using fed-batch cultures.
For more than 20 years, Selexis has been at the forefront of helping the biopharmaceutical industry advance life-saving monoclonal antibodies through all the steps from IND filling, clinical phases, to market launch and commericialization.
At Selexis, we believe in the promise of newer biologics and have committed significant resources to ensure our SUREtechnology Platform™ can meet the new expression challenges that these difficult-to-express proteins present.
We are proud of the role that Selexis’ cell line technology is playing in helping to deliver on the promise of bispecifics, which is a rapidly expanding class of drugs showing impressive results in multiple clinical trials.
Copyright© 2023 Selexis SA. All Rights Reserved.